Technical Analysis for NRXP - NeuroRx, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 1.39 | 1.09% | 0.02 |
NRXP closed up 1.09 percent on Friday, November 1, 2024, on 22 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
Earnings due: Nov 11
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
1,2,3 Retracement Bearish | Bearish Swing Setup | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
Stochastic Reached Overbought | Strength | 0.00% | |
Weak + Overbought | Other | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
1,2,3 Retracement Bearish | Bearish Swing Setup | 1.09% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 1.09% | |
20 DMA Support | Bullish | 1.09% |
Alert | Time |
---|---|
Up 1% | about 21 hours ago |
Possible Inside Day | about 21 hours ago |
Down 2 % | about 24 hours ago |
Down 1% | about 24 hours ago |
10 DMA Support | 2 days ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/11/2024
NeuroRx, Inc. operates as a clinical stage-small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders. Its drug candidate includes Cyclurad, an oral therapeutic for the treatment of acute/elevated suicidal ideation/crisis in bipolar depression. The company was incorporated in 2015 and is headquartered in Wilmington, Delaware.
Sector: Industrials
Industry: Conglomerates
Keywords: Life Sciences Health Sciences Health Care Central Nervous System Disorders Antidepressants Bipolar Disorder Treatment Of Central Nervous System Disorders Atypical Antipsychotics Bipolar Depression
Classification
Sector: Industrials
Industry: Conglomerates
Keywords: Life Sciences Health Sciences Health Care Central Nervous System Disorders Antidepressants Bipolar Disorder Treatment Of Central Nervous System Disorders Atypical Antipsychotics Bipolar Depression
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 7.333 |
52 Week Low | 1.1 |
Average Volume | 116,099 |
200-Day Moving Average | 3.07 |
50-Day Moving Average | 1.55 |
20-Day Moving Average | 1.31 |
10-Day Moving Average | 1.28 |
Average True Range | 0.11 |
RSI (14) | 49.24 |
ADX | 31.82 |
+DI | 17.79 |
-DI | 20.38 |
Chandelier Exit (Long, 3 ATRs) | 1.34 |
Chandelier Exit (Short, 3 ATRs) | 1.43 |
Upper Bollinger Bands | 1.51 |
Lower Bollinger Band | 1.12 |
Percent B (%b) | 0.68 |
BandWidth | 30.07 |
MACD Line | -0.07 |
MACD Signal Line | -0.10 |
MACD Histogram | 0.0335 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.49 | ||||
Resistance 3 (R3) | 1.48 | 1.43 | 1.47 | ||
Resistance 2 (R2) | 1.43 | 1.41 | 1.44 | 1.46 | |
Resistance 1 (R1) | 1.41 | 1.39 | 1.42 | 1.42 | 1.46 |
Pivot Point | 1.37 | 1.37 | 1.37 | 1.37 | 1.37 |
Support 1 (S1) | 1.34 | 1.34 | 1.35 | 1.35 | 1.31 |
Support 2 (S2) | 1.30 | 1.32 | 1.30 | 1.31 | |
Support 3 (S3) | 1.27 | 1.30 | 1.30 | ||
Support 4 (S4) | 1.28 |